Clinical trials: Morphine
Pain
A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain
Tapentadol has already been studied in adults. This study is needed to find out if tapentadol works and is safe to use in children and adolescents with long-term pain.
- Trial name
- NCT02151682
- Testing
- Tapentadol prolonged release, Morphine prolonged release
- Where
- 23 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 73 people
- Sponsor
- Grünenthal GmbH
Relapsing Multiple Sclerosis
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod
- Trial name
- FLUENT (NCT03257358)
- Testing
- Fingolimod
- Where
- 66 sites in United States
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions
The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of morphine sulfate 200 mg sustained-release capsules…
- Trial name
- NCT00759759
- Testing
- morphine sulfate sustained-release capsules, KADIAN (morphine sulfate sustained-release) capsules
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Relapsing Multiple Sclerosis (RMS)
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV…
- Trial name
- ULTIMATE 1 (NCT03277261)
- Testing
- Ublituximab, Teriflunomide
- Where
- 14 sites in United States
- Volunteers
- 549 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary…
- Trial name
- GEMINI 1 (NCT04410978)
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 179 sites in United States, Austria and 22 more
- Volunteers
- 974 people
- Sponsor
- Sanofi
Multiple Sclerosis
Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
Randomized, double-blind, placebo-controlled Phase IIa clinical study, assessing safety, tolerability, pharmacodynamic effects and pharmacokinetics of temelimab, administered at three different dose levels (18 mg/kg or 36 mg/kg…
- Trial name
- ProTEct-MS (NCT04480307)
- Testing
- temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg
- Where
- Sweden
- Volunteers
- 41 people
- Sponsor
- GeNeuro Innovation SAS
Pain
Safety and Pharmacokinetic Study of Oral Morphine Sulfate in Pediatric Subjects
The purpose of this study is to evaluate the tolerability and safety of oral morphine sulfate in the treatment of postoperative pain in different pediatric age groups following multiple-dose administration.
- Trial name
- NCT01322360
- Testing
- Morphine Sulfate
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- Roxane Laboratories
Respiratory Monitoring
Comparison of Non-invasive Respiratory Monitoring System (RMS) to Capnography for Respiratory Rate (RR)
The goal of this clinical trial is to compare the performance of a novel non-invasive respiratory monitoring system against the gold standard methods (capnography) in human subjects.
- Trial name
- NCT06521385
- Testing
- Makani Science Respiratory Monitoring System
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Makani Science
Mucopolysaccharidosis IVA, Morquio A Syndrome
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01609062
- Testing
- BMN 110
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 25 people
- Sponsor
- BioMarin Pharmaceutical
Relapsing Multiple Sclerosis
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy
- Trial name
- OLIKOS (NCT04486716)
- Testing
- Ofatumumab
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in subjects with clinically isolated syndrome (CIS) or…
- Trial name
- PROCEED (NCT02254304)
- Testing
- Rebif
- Where
- Germany
- Volunteers
- 106 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
The Electronic Device - The RebiSmart™ is an electronic injection device that is being studied for the delivery of Merck Serono's Rebif® New Formulation.
- Trial name
- NCT00735007
- Testing
- Rebif® New Formulation (RNF) using RebiSmartTM
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- EMD Serono
Relapsing-remitting Multiple Sclerosis
Study of Evobrutinib in Participants With RMS
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with Relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT04032171
- Testing
- Evobrutinib, Avonex®
- Where
- 2 sites in United States, Germany
- Volunteers
- 1 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis (RMS)
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
The main purpose of this study was to assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT04667949
- Testing
- Fingolimod 0.5mg
- Where
- 13 sites in China
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
Primary Objective: To describe efficacy, tolerability and convenience of teriflunomide treatment through the evaluation of Participant Reported Outcomes (PROs). Secondary Objectives: To describe disease progression using PROs.
- Trial name
- TERI-PRO (NCT01895335)
- Testing
- Teriflunomide
- Where
- 169 sites in United States, Austria and 12 more
- Volunteers
- 1,001 people
- Sponsor
- Sanofi
Healthy
Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce
The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of morphine sulfate 200 mg sustained-release capsules…
- Trial name
- NCT00759954
- Testing
- morphine sulfate sustained-release capsules, KADIAN (morphine sulfate sustained-release) capsules
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Healthy
Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions
The objective of this single-dose, open-label, randomized, two-treatment, two-period crossover study was to compare the relative bioavailability of a test formulation of KADIAN (2 x 10 mg) capsules manufactured by Alpharma Inc.
- Trial name
- NCT00759902
- Testing
- morphine sulfate extended-release capsules, KADIAN (morphine sulfate extended-release) capsules
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Cancer Pain
A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain
The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorohone Hydrochloride (HCl) compared with morphine sustain release (SR) in participants with chronic (lasting a…
- Trial name
- NCT00803283
- Testing
- Hydromprphone Hydrochloride (HCl) OROS, Morphine Sustain Release (SR)
- Volunteers
- 2 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Multiple Sclerosis
The Multicenter, Open-label, Single-use Autoinjector Convenience Study
The purpose of this trial is to test the Single-Use Autoinjector for a) ease of use; b) multiple domains related to subject's acceptability and satisfaction, and c) reliability of the correct function for self-injection of Rebif®…
- Trial name
- NCT00958009
- Testing
- Rebidose®
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- EMD Serono
Pain, Neoplasms
CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer
Pain is one of the most common symptoms associated with malignant tumor. The purpose of this trial is to determine whether cebranopadol is as effective in patients with cancer related pain as morphine sulfate prolonged release…
- Conditions
- Pain, Neoplasms, Chronic Pain
- Trial name
- CORAL (NCT01964378)
- Testing
- Cebranopadol, Morphine Prolonged Release
- Where
- 42 sites in Austria, Belgium and 12 more
- Volunteers
- 200 people
- Sponsor
- Tris Pharma, Inc.